Drugs / Conditioned Medium
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05008588 | May 2022 → Mar 2026 overdue | ischemic stroke | PT. Prodia Stem Cell Indonesia | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04314687 | Oct 2021 → Jul 2026 overdue | cerebral palsy | PT. Prodia Stem Cell Indonesia | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04326959 | Sep 2020 | keloid | PT. Prodia Stem Cell Indonesia | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT04315025 Comparator | Oct 2018 → Jun 2019 | retinitis pigmentosa | PT. Prodia Stem Cell Indonesia | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Conditioned Medium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04326959 ↗ |
| Route | Intrathecal | “UCMSCs + CM is administered via intrathecal injection” NCT04314687 ↗ |